DK3518933T3 - Fremgangsmåder til behandling af uterusfibromer og endometriose - Google Patents

Fremgangsmåder til behandling af uterusfibromer og endometriose Download PDF

Info

Publication number
DK3518933T3
DK3518933T3 DK17823018.1T DK17823018T DK3518933T3 DK 3518933 T3 DK3518933 T3 DK 3518933T3 DK 17823018 T DK17823018 T DK 17823018T DK 3518933 T3 DK3518933 T3 DK 3518933T3
Authority
DK
Denmark
Prior art keywords
fibromes
endometriosis
uterus
procedures
treatment
Prior art date
Application number
DK17823018.1T
Other languages
English (en)
Inventor
Jr Paul N Mudd
Susan Wollowitz
Mark Hibberd
Vijaykumar Reddy Rajasekhar
Lynn Seely
Mayukh Vasant Sukhatme
Masataka Tanimoto
Brendan Mark Johnson
Original Assignee
Myovant Sciences Gmbh
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3518933(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myovant Sciences Gmbh, Takeda Pharmaceuticals Co filed Critical Myovant Sciences Gmbh
Application granted granted Critical
Publication of DK3518933T3 publication Critical patent/DK3518933T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
DK17823018.1T 2016-09-30 2017-09-29 Fremgangsmåder til behandling af uterusfibromer og endometriose DK3518933T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662402055P 2016-09-30 2016-09-30
US201662402150P 2016-09-30 2016-09-30
US201662402034P 2016-09-30 2016-09-30
US201762492839P 2017-05-01 2017-05-01
US201762528409P 2017-07-03 2017-07-03
PCT/EP2017/074907 WO2018060501A2 (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis

Publications (1)

Publication Number Publication Date
DK3518933T3 true DK3518933T3 (da) 2022-05-30

Family

ID=60915460

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17823018.1T DK3518933T3 (da) 2016-09-30 2017-09-29 Fremgangsmåder til behandling af uterusfibromer og endometriose

Country Status (21)

Country Link
US (4) US11033551B2 (da)
EP (2) EP3518933B1 (da)
JP (1) JP7043503B2 (da)
CN (1) CN110312512B (da)
AU (2) AU2017336363B2 (da)
BR (1) BR112019006227A2 (da)
CA (1) CA3038879A1 (da)
DK (1) DK3518933T3 (da)
ES (1) ES2912929T3 (da)
HR (1) HRP20220708T1 (da)
HU (1) HUE059101T2 (da)
IL (2) IL300580A (da)
LT (1) LT3518933T (da)
MD (1) MD3518933T2 (da)
MX (1) MX2019003726A (da)
NZ (1) NZ752916A (da)
PL (1) PL3518933T3 (da)
PT (1) PT3518933T (da)
RS (1) RS63300B1 (da)
SI (1) SI3518933T1 (da)
WO (1) WO2018060501A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300580A (en) 2016-09-30 2023-04-01 Takeda Pharmaceuticals Co Methods for treating uterine fibroids and endometrial disease
MX2019003733A (es) 2016-09-30 2019-09-26 Myovant Sciences Gmbh Tratamiento de cancer de prostata.
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
CN110996957A (zh) 2017-06-05 2020-04-10 奥布赛瓦股份公司 用于治疗子宫肌瘤并减少月经失血的促性腺激素释放激素拮抗剂给药方案
JP2021531236A (ja) * 2018-04-19 2021-11-18 アッヴィ・インコーポレイテッド 重度の月経出血を治療する方法
CA3117092A1 (en) * 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
RU2711658C1 (ru) * 2019-04-16 2020-01-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения наружного генитального эндометриоза
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
KR20220061120A (ko) * 2019-08-08 2022-05-12 옵스에파 에스에이 에스트로겐-의존성 장애 치료용 조성물 및 방법
WO2021069711A1 (en) * 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea
WO2021069700A1 (en) * 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
UY39229A (es) 2020-05-29 2021-12-31 Myovant Sciences Gmbh Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2024015934A2 (en) * 2022-07-13 2024-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of diagnostic screening and early detection of adenomyosis

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US492839A (en) 1893-03-07 Key for brake-shoes
US402055A (en) 1889-04-23 Water-motor
US402150A (en) 1889-04-30 Broadcast seed-sower
US402034A (en) 1889-04-23 Dumping-wagon
US528409A (en) 1894-10-30 Denis ahern
FR2512732A1 (fr) 1981-09-14 1983-03-18 Raffinage Cie Francaise Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
ECSP961635A (es) 1996-01-11 1997-06-27 Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es) 1997-01-15 1998-04-07 Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de) 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
US6297379B1 (en) 1999-03-24 2001-10-02 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
CN1539836A (zh) 2000-02-29 2004-10-27 武田药品工业株式会社 制备噻吩并嘧啶衍生物的方法
US7569570B2 (en) 2002-01-30 2009-08-04 Takeda Pharmaceutical Company Limited Thienopyrimidines, process for preparing the same and use thereof
AU2004207706B2 (en) 2003-01-29 2010-03-04 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
EA010370B1 (ru) 2003-07-07 2008-08-29 Ньюрокрайн Байосайенсиз, Инк. Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
EP1917978B1 (en) 2005-07-22 2014-08-20 Takeda Pharmaceutical Company Limited Premature ovulation preventive agent
AR058584A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Derivados de metastina y uso de los mismos
NZ580457A (en) 2007-04-06 2012-03-30 Neurocrine Biosciences Inc Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
EP2329823A4 (en) 2008-09-03 2013-04-03 Takeda Pharmaceutical METHOD FOR IMPROVING CAPACITY OF PREPARATION TO BE ABSORBED AND PREPARATION WHICH CAPACITY TO BE ABSORBED IS IMPROVED
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US11576891B2 (en) 2010-06-16 2023-02-14 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
JP2012077020A (ja) 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
ES2724206T3 (es) 2012-09-28 2019-09-09 Takeda Pharmaceuticals Co Método de producción de un derivado de tienopirimidina
EP3384930A1 (en) * 2013-03-15 2018-10-10 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding
CA2978223A1 (en) 2015-02-26 2016-09-01 Takeda Pharmaceutical Company Limited Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
AU2016317955B2 (en) 2015-09-01 2021-05-20 Abbvie Inc. Methods of administering Elagolix
MX2019003733A (es) 2016-09-30 2019-09-26 Myovant Sciences Gmbh Tratamiento de cancer de prostata.
IL300580A (en) 2016-09-30 2023-04-01 Takeda Pharmaceuticals Co Methods for treating uterine fibroids and endometrial disease
US11980621B2 (en) 2017-06-05 2024-05-14 Kissei Pharmaceutical Co., Ltd. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
WO2021069700A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
WO2021069711A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea
UY39229A (es) 2020-05-29 2021-12-31 Myovant Sciences Gmbh Formas de dosificación oral sólidas de combinación de antagonistas de la hormona liberadora de gonadotropina
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
WO2023066941A1 (en) 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Also Published As

Publication number Publication date
RS63300B1 (sr) 2022-07-29
US20220370462A1 (en) 2022-11-24
CA3038879A1 (en) 2018-04-05
US20190262346A1 (en) 2019-08-29
AU2017336363A1 (en) 2019-05-16
WO2018060501A2 (en) 2018-04-05
LT3518933T (lt) 2022-06-10
CN110312512B (zh) 2023-05-09
HUE059101T2 (hu) 2022-10-28
ES2912929T3 (es) 2022-05-30
JP7043503B2 (ja) 2022-03-29
US20240165118A1 (en) 2024-05-23
NZ752916A (en) 2022-09-30
CN110312512A (zh) 2019-10-08
EP4094766A1 (en) 2022-11-30
PL3518933T3 (pl) 2022-06-20
IL265700B1 (en) 2023-03-01
MX2019003726A (es) 2019-09-26
AU2022241582A1 (en) 2022-10-27
EP3518933B1 (en) 2022-03-16
MD3518933T2 (ro) 2022-07-31
PT3518933T (pt) 2022-05-10
US11957684B2 (en) 2024-04-16
IL265700A (en) 2019-05-30
AU2017336363B2 (en) 2022-08-04
IL265700B2 (en) 2023-07-01
US11033551B2 (en) 2021-06-15
US20210401841A1 (en) 2021-12-30
SI3518933T1 (sl) 2022-06-30
EP3518933A2 (en) 2019-08-07
BR112019006227A2 (pt) 2019-06-18
HRP20220708T1 (hr) 2022-07-22
WO2018060501A3 (en) 2018-05-11
IL300580A (en) 2023-04-01
JP2019529575A (ja) 2019-10-17
US11793812B2 (en) 2023-10-24

Similar Documents

Publication Publication Date Title
DK3518933T3 (da) Fremgangsmåder til behandling af uterusfibromer og endometriose
DK3264955T3 (da) Blandeanordning og fremgangsmåde
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3402888T3 (da) Middel og fremgangsmåder til behandling af hbv
DK3286181T3 (da) Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne
DK3380101T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3442580T3 (da) Fremgangsmåder til behandling af kolestatiske og fibrotiske sygdomme
DK3319611T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3224269T3 (da) Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3430038T3 (da) Sammensætninger og fremgangsmåder til cd20-immunterapi
DK3558280T3 (da) Forebyggelse og behandling af migræne
DK3436022T3 (da) Oxysteroler og fremgangsmåder til anvendelse heraf
DK3234098T3 (da) Anordning og fremgangsmåde til påvisning af plantepatogener
DK3096684T3 (da) Anordning og fremgangsmåde til måling af kropsegenskaber
DK3194328T3 (da) Gelformpude og fremgangsmåde til fremstilling af samme
DK3183010T3 (da) Anordning og tilhørende fremgangsmåde til behandling af medicinsk affald
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3414420T3 (da) Brøndanordning og brøndsystem
DK3191103T3 (da) Sammensætninger og fremgangsmåder til behandling af præcancerøse hudlæsioner